J. Settleman
Oncology · 2004–2012
A researcher in the Science corpus: 14 papers; trusts 4 researchers and is trusted by 10 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 171 citations into it; #178 of 1,698 by trust here, #135 by citations
- Molecular Biology — 159 citations into it
- Cell Biology — 29 citations into it
- Hematology — 18 citations into it
Whom J. Settleman trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts J. Settleman overall
Papers from J. Settleman's perspective
Ordered by how strongly the researchers J. Settleman trusts endorse each paper. Same corpus, a different order for every researcher.
- The epithelial-mesenchymal transition generates cells with properties of stem cells. (Cell)
- The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. (Genes & Development)
- Prospective identification of tumorigenic breast cancer cells (Proceedings of the National Academy of Sciences of the United States of America)
- The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 (Nature Cell Biology)
- Identification and expansion of human colon-cancer-initiating cells (Nature)
- Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. (Cancer Research)
- Identification of selective inhibitors of cancer stem cells by high-throughput screening (Cell)
- Molecular definition of breast tumor heterogeneity. (Cancer Cell)
- Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? (Nature Reviews. Cancer)
- Efficient tumor formation by single human melanoma cells (Nature)
Their papers
- Systematic identification of genomic markers of drug sensitivity in cancer cells (2012) — 2,417 citations
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors (2012) — 1,147 citations
- A chromatin-mediated reversible drug tolerant state in cancer cell subpopulations (2010) — 2,613 citations
- EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib (2012) — 944 citations
- Epidermal growth factor receptor mutations in lung cancer (2007) — 3,159 citations
- A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. (2009) — 830 citations
- SCFFbw7 Regulates Cellular Apoptosis By Targeting Mcl-1 for Ubiquitination and Destruction (2011) — 602 citations
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer (2010) — 2,601 citations
- Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. (2009) — 1,860 citations
- First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. (2008) — 865 citations
- Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes (2008) — 2,657 citations
- Detection of mutations in EGFR in circulating lung-cancer cells. (2008) — 1,564 citations
- Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. (2005) — 972 citations
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (2004) — 1,654 citations